|
Health and human rights: Provision of treatment in HIV-1 vaccine trials in developing countries Fitzgerald DW, et al.
The Lancet
362(9388), 20 September 2003
Link Should volunteers who become HIV-1 infected during the course of HIV-1 vaccine trials in developing countries be provided with antiretroviral therapy by investigators? Despite emotionally charged debate, consensus on this issue has not been reached. For example, UNAIDS ethics guidelines for HIV vaccine research do not set one standard of care, but rather provide an acceptable range between a minimum and the ideal. The HIV Vaccine Trials Network (HVTN), a collaboration of scientists from 28 research sites (figure), announced this year that participants who become infected during HVTN vaccine trials will receive long-term antiretroviral treatment. The decision was based on three arguments.
—Posted: September 23, 2003
More journal headlines: This month | Last month | Search archive
|
